Patrick Lin insider trades
Open-market stock purchases and sales by Patrick Lin, Chief Business - Strategy Off at Processa Pharmaceuticals, Inc, from SEC Form 4 filings since Oct 1, 2020.
Track record: 11% of 18 scored buys are up 5% or more since purchase, averaging -21%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 15, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| May 29, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| May 15, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| Apr 30, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| Apr 15, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| Mar 31, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought | $4.1K |
| Jan 1, 2026 | PCSA Processa Pharmaceuticals, Inc | Bought (not open market) | — |
Companies traded
- PCSA Processa Pharmaceuticals, Inc: 19 buys, last Jun 15, 2026